Deals
Merrill Alum Brings Foreign Biotech to Taiwan in IPO Market Boon
- Singapore drug developer Aslan chooses Taiwan for listing
- AstraZeneca veterans seek to raise $40 million in share sale
Carl Firth.
Source: ASLAN PharmaceuticalsThis article is for subscribers only.
A Singaporean biotechnology company working on experimental cancer drugs is listing in Taiwan, potentially opening the door for more foreign peers to go public on the island.
Aslan Pharmaceuticals Pte, led by former AstraZeneca Plc executives, will take investor orders for its initial public offering in mid-May with the goal of listing by the end of that month, Chief Executive Officer Carl Firth said in an interview. Firth headed Asia health-care investment banking for Merrill Lynch, which is now a unit of Bank of America Corp., from 2007 to 2010.